Zobrazeno 1 - 10
of 256
pro vyhledávání: '"Olaratumab"'
Autor:
Leo Mascarenhas, Chitose Ogawa, Theodore W. Laetsch, Brenda J. Weigel, Michael W. Bishop, Julie Krystal, Scott C. Borinstein, Emily K. Slotkin, Jodi A. Muscal, Pooja Hingorani, Donna E. Levy, Gary Mo, Ashwin Shahir, Jennifer Wright, Steven G. DuBois
Publikováno v:
Cancer Medicine, Vol 10, Iss 3, Pp 843-856 (2021)
Abstract Olaratumab is a monoclonal antibody that specifically binds to platelet‐derived growth factor receptor alpha (PDGFRα) and blocks receptor activation. We conducted a phase 1 trial to evaluate the safety of olaratumab and determine a recomm
Externí odkaz:
https://doaj.org/article/728f5f60eab94b5f8c5a384248851207
Publikováno v:
Therapeutics and Clinical Risk Management, Vol Volume 16, Pp 141-146 (2020)
Anastasios Kyriazoglou, 1 Konstantinos Koutsoukos, 1 Flora Zagouri, 1 Michalis Liontos, 1 Efthimios Dimitriadis, 2 Dina Tiniakos, 3, 4 Meletios Athanasios Dimopoulos 1 1Department of Clinical Therapeutics, General Hospital Alexandra, Athens, Greece;
Externí odkaz:
https://doaj.org/article/b68771081f1d4a1aa43e7c3169c4d690
Autor:
Victor M. Villalobos, Gary Mo, Mark Agulnik, Seth M. Pollack, Daniel A. Rushing, Arun Singh, Brian A. Van Tine, Rhian McNaughton, Rodney L. Decker, Wei Zhang, Ashwin Shahir, Damien M. Cronier
Publikováno v:
Cancer Medicine, Vol 9, Iss 3, Pp 882-893 (2020)
Abstract Background Olaratumab, a fully human monoclonal antibody, selectively binds to human platelet‐derived growth factor receptor alpha and blocks ligand binding. This study assessed the effect of olaratumab on the pharmacokinetics (PK) of doxo
Externí odkaz:
https://doaj.org/article/ea5713e478994fba9c19d01324de61f2
Autor:
Jana Käthe Striefler, Franziska Brandes, Alexander Baur, Berit Maria Pfitzner, David Kaul, Daniel Rau, Anne Dörr, Maren Schmiester, Georgios Koulaxouzidis, Lars Bullinger, Sven Märdian, Anne Flörcken
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
Abstract Background The antibody targeting platelet-derived growth factor receptor alpha (PDGFRA), olaratumab, was approved in 2016 for metastatic soft tissue sarcoma (STS) in combination with doxorubicin based on promising results of a phase Ib/II t
Externí odkaz:
https://doaj.org/article/5891a1100257426da57b6d8cb43f04a3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jasmien Cornillie, Agnieszka Wozniak, Britt Van Renterghem, Nathalie Van Winkel, Jasmien Wellens, Yemarshet K. Gebreyohannes, Maria Debiec-Rychter, Raf Sciot, Daphne Hompes, Patrick Schöffski
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-12 (2019)
Abstract Background Soft tissue sarcoma (STS) comprises a family of rare, heterogeneous tumors of mesenchymal origin. Single-agent doxorubicin remains the first-line standard-of-care treatment for advanced and inoperable STS, but response rates are o
Externí odkaz:
https://doaj.org/article/04a447b35404461fae43948d5d350cc7
Publikováno v:
Precision and Future Medicine, Vol 3, Iss 2, Pp 77-84 (2019)
Purpose Soft tissue sarcomas (STS) are a rare and heterogeneous tumor group with limited treatment options. This study aimed to evaluate the anti-tumor efficacy of olaratumab and doxorubicin in patients with advanced STS in front-line and salvage set
Externí odkaz:
https://doaj.org/article/b9e1440d4b0a4bed9be3f332ca239856
Autor:
William P. McGuire, Richard T. Penson, Martin Gore, Antonio Casado Herraez, Patrick Peterson, Ashwin Shahir, Robert Ilaria
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background Olaratumab is a platelet-derived growth factor receptor-α (PDGFRα)-targeting monoclonal antibody blocking PDGFRα signaling. PDGFRα expression is associated with a more aggressive phenotype and poor ovarian cancer outcomes. Thi
Externí odkaz:
https://doaj.org/article/aec05d6fed2e4b8d95e91fcd8dfd28b0
Autor:
Elizabeth J. Davis, Vicki L. Keedy
Publikováno v:
European Medical Journal Oncology, Vol 6, Iss 1, Pp 91-101 (2018)
Soft tissue sarcomas (STS) are a rare group of heterogeneous malignancies with >50 histologic subtypes that have varying biological behaviour and responsiveness to systemic therapy. The mainstay of therapy for metastatic STS in recent decades has bee
Externí odkaz:
https://doaj.org/article/82b560800a2f48f8a153af1c886960ab
Publikováno v:
Clinical Pharmacology: Advances and Applications, Vol Volume 9, Pp 159-164 (2017)
Alexandra Pender,1 Robin L Jones1,2 1Sarcoma Unit, Department of Medicine, The Royal Marsden NHS Foundation Trust, 2Division of Clinical Studies, The Institute of Cancer Research, London, UK Abstract: The outcome of patients with unresectable or meta
Externí odkaz:
https://doaj.org/article/61c57060328d44beabb0ff5b9876a106